Usama Gergis joined The Sidney Kimmel Cancer Center–Jefferson Health as director of the Bone Marrow Transplant and Immune Cellular Therapy Program and professor in the Department of Medical Oncology, Division of Hematological Malignancies.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
